0KBS Stock Chart & Stats
€50.40
€0.25(0.48%)
At close: 4:00 PM EST
€50.40
€0.25(0.48%)
Day’s Range― - ―
52-Week Range€43.78 - €55.10
Previous CloseN/A
Volume7.51K
Average Volume (3M)7.60K
Market Cap
€10.66B
Enterprise Value€12.60K
Total Cash (Recent Filing)€391.38M
Total Debt (Recent Filing)€2.31B
Price to Earnings (P/E)21.3
Beta0.77
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.43
Shares Outstanding209,125,150
10 Day Avg. Volume8,262
30 Day Avg. Volume7,601
Financial Highlights & Ratios
PEG Ratio3.24
Price to Book (P/B)5.20
Price to Sales (P/S)3.81
P/FCF Ratio19.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€50.00Price Target Upside-0.79% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)3.17
Revenue Forecast (FY)€2.78B
Bulls Say, Bears Say
Bulls Say
High Profitability / MarginsRecordati’s consistently high gross and EBITDA margins indicate durable pricing power and efficient core operations across periods. Sustained margin levels support internal R&D funding, steady operating cash generation and the ability to maintain shareholder returns even if top-line growth slows.
Strong Free Cash Flow GenerationRobust trailing twelve-month free cash flow and solid conversion of earnings into cash provide enduring financial flexibility. This cash generation underpins reinvestment in product development, manufacturing capacity, dividend payments and optional debt reduction, reinforcing long-term operational stability.
Diversified Branded & Rare-disease FranchiseA mixed model of established branded products and higher-value rare-disease therapies creates durable revenue diversification. End-to-end capabilities (R&D, manufacturing, sales) and specialized market-access expertise for orphan drugs support sustainable margins and lower dependence on any single product or market.
Bears Say
Elevated Financial LeverageLeverage materially above historical (and peer) norms increases financial risk and reduces flexibility. Higher debt levels elevate interest burden, constrain capital allocation choices for M&A or R&D, and make the company more sensitive to cash-flow shocks or rising rates despite recent moderation in leverage.
Cash Flow VolatilityIntermittent swings in operating and free cash flow complicate long-term planning. Volatility may force short-term financing or deferment of investments in weaker years, increasing refinancing and execution risk for R&D programs and commercialization investments despite strong TTM cash.
Margins Below Prior PeakMargins that have eased from the 2021 peak suggest structural mix shifts, cost pressures or pricing/reimbursement headwinds. Persisting margin compression would limit incremental profit growth from revenue gains and could constrain free cash flow expansion over the medium term.
Recordati Industria Chimica e Farmaceutica SPA News
0KBS FAQ
What was Recordati Industria Chimica e Farmaceutica SPA’s price range in the past 12 months?
Recordati Industria Chimica e Farmaceutica SPA lowest share price was €43.78 and its highest was €55.10 in the past 12 months.
What is Recordati Industria Chimica e Farmaceutica SPA’s market cap?
Recordati Industria Chimica e Farmaceutica SPA’s market cap is €10.66B.
When is Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date?
Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date is Nov 10, 2026 which is in 96 days.
How were Recordati Industria Chimica e Farmaceutica SPA’s earnings last quarter?
Recordati Industria Chimica e Farmaceutica SPA released its earnings results on Jul 28, 2026. The company reported €1.292 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Recordati Industria Chimica e Farmaceutica SPA overvalued?
According to Wall Street analysts Recordati Industria Chimica e Farmaceutica SPA’s price is currently Overvalued.
Does Recordati Industria Chimica e Farmaceutica SPA pay dividends?
Recordati Industria Chimica e Farmaceutica SPA does not currently pay dividends.
What is Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate?
Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recordati Industria Chimica e Farmaceutica SPA have?
Recordati Industria Chimica e Farmaceutica SPA has 209,125,150 shares outstanding.
What happened to Recordati Industria Chimica e Farmaceutica SPA’s price movement after its last earnings report?
Recordati Industria Chimica e Farmaceutica SPA reported an EPS of €1.292 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.292%.
Which hedge fund is a major shareholder of Recordati Industria Chimica e Farmaceutica SPA?
Currently, no hedge funds are holding shares in GB:0KBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
0KBS Stock 12 Month Forecast
Average Price Target
€50.00
▼(-0.79% Downside)